^




Show legend
Group by Gene:
Include preclinical:

Aybintio (bevacizumab biosimilar)
Zirabev (bevacizumab biosimilar)
0
VEGF-A inhibitor
bevacizumab
Krabeva (bevacizumab biosimilar)
Bevax (bevacizumab biosimilar)
Mvasi (bevacizumab biosimilar)
cabozantinib tablet
1
Multi-tyrosine kinase inhibitor
pazopanib
cabozantinib capsule
everolimus
2
mTOR inhibitor
temsirolimus
sirolimus
mTOR inhibitor
nivolumab
pembrolizumab
3
PD1 inhibitor
dostarlimab
toripalimab
PD1 inhibitor
4
IFNα stimulant, VEGF-A inhibitor
bevacizumab + pegylated interferon α -2a
Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
5
VEGFR inhibitor, PD1 inhibitor
pembrolizumab + axitinib
6
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
7
PD1 inhibitor, Multi-tyrosine kinase inhibitor
nivolumab + cabozantinib tablet
8
VEGF-A inhibitor, EGFR inhibitor
bevacizumab + erlotinib
9
VEGFR inhibitor, PD-L1 inhibitor
avelumab + axitinib
10
VEGFR inhibitor
axitinib
11
EGFR inhibitor
erlotinib
12
HIF-2α inhibitor
belzutifan
PT2385
13
ALK inhibitor
crizotinib
alectinib
14
c-MET inhibitor
savolitinib
c-MET inhibitor
atezolizumab
15
PD-L1 inhibitor
avelumab
PD-L1 inhibitor
16
PARP inhibitor
olaparib
17
HDAC inhibitor, Multi-tyrosine kinase inhibitor
pazopanib + CG-781
18
BRAF inhibitor
vemurafenib
19
VEGF-A inhibitor, PI3Kγ inhibitor, Tubulin inhibitor
bevacizumab + albumin-bound paclitaxel + IPI-549
20
FGFR inhibitor
ABSK-091
21
VEGFR inhibitor, mTOR inhibitor
temsirolimus + axitinib
22
PD1 inhibitor, IDO1 inhibitor
nivolumab + BMS-986205
pembrolizumab + INCB024360
23
mTORC1 inhibitor, mTORC2 inhibitor
TAK-228
24
ALK inhibitor, Multi-tyrosine kinase inhibitor
crizotinib + pazopanib
25
VEGFR-2 inhibitor, c-MET inhibitor
GSK1363089
26
VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
sunitinib
27
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
lenvatinib
28
VEGFR-2 inhibitor, RAF kinase inhibitor, BRAF inhibitor, PDGFR β antagonist
sorafenib
29
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
pembrolizumab + lenvatinib
30
VEGFR-3 antagonist, VEGFR-2 inhibitor, VEGFR-1 antagonist
tivozanib
31
FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
everolimus + lenvatinib
32
CD122 agonist, IL-2 stimulant
aldesleukin
33
PD-L1 inhibitor, VEGF-A inhibitor
bevacizumab + atezolizumab
34
CDK4 inhibitor, CDK6 inhibitor
palbociclib
35
PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
bevacizumab + atezolizumab + IPI-549
36
TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
CDX-014
37
VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
sunitinib + pazopanib
38
VEGFR-2 inhibitor, RAF kinase inhibitor, Hyaluronic acid synthase inhibitor, BRAF inhibitor, PDGFR β antagonist
sorafenib + 4-methylumbelliferone
39
PRC2 inhibitor
MRTX2219
40
MEK2 inhibitor, MEK1 inhibitor
U0126
41
RAC1 inhibitor
NSC23766
42
Topoisomerase II inhibitor
doxorubicin hydrochloride
43
VEGFR inhibitor, PDGFR inhibitor, VEGFR-2 inhibitor, RAF kinase inhibitor, BRAF inhibitor, c-KIT inhibitor, PDGFR β antagonist
sorafenib + sunitinib
44
CYP17A1 inhibitor
abiraterone acetate
45
DNA synthesis inhibitor
cisplatin
46
Glutamate inhibitor
Glutamate inhibitor
47
Immunotherapy
Immunotherapy
48
Tyrosine kinase inhibitor
Tyrosine kinase inhibitor
49
VEGF inhibitor
VEGF inhibitor
No biomarker
PD-L1 expression
PD-L1 underexpression
PD-L1 overexpression
MET mutation
MET amplification
MET fusion
KDR rs2071559
KDR C482R
KDR expression
MTOR mutation
FLT1 rs9554320
PBRM1 mutation
PBRM1 overexpression
PBRM1 deletion
FLT1 expression
PBRM1 negative
MTOR Q2223K
PBRM1 underexpression
ARID1A mutation
ROBO3 mutation
AXL-L
AXL overexpression
AXL expression
VHL mutation
ALK rearrangement
PD-1 expression
HGF expression
TSC1 mutation
TSC2 mutation
TSC1 deletion
TSC2 H1620R + TSC2 Y1650C
HMOX1 expression
HGF-L
HMOX1-L
VHL promoter methylation
HGF-H
PD-1-H
FH mutation
TIMP1 expression
CSF1 expression
VEGFA expression
CXCL9 expression
IL18BP expression
SYNE1 mutation
ERVE-4 expression
CDKN2A mutation
CEACAM1 overexpression
CXCL10 overexpression
CA9 expression
CD31 expression
GNAQ mutation
IKZF2-L
KDM5C mutation
PDGFRA expression
HDAC2 expression
CD8 expression
HIF1A expression
TFE3 translocation
FLCN mutation
LRP1B mutation
ELTD1 expression
KIM1 expression
BRCA2 mutation
BRCA1 mutation
BAP1 negative
IL6R L
IL6-L
IL6ST-H
TFEB translocation
EWSR1-POU5F1 fusion
KMT2C mutation
LDH elevation
CTLA4 promoter hypomethylation
NANOGNB mutation
ANGPT2 expression
PBRM1 mutation + SETD2 mutation
TERT promoter mutation
BRAF mutation
miR138 underexpression + miR497 overexpression
HAVCR2 expression
SPP1-L
CXCL8-L
IL18 expression
IL6-H
CXCL8 elevation
BAP1 mutation
CXCL10-H
VEGFA-H
BAP1 deletion
KIM1 elevation
IL6 elevation
CDKN2A deletion
TERT overexpression
FLCN deletion
T-cell-inflamed GEP signature
IFNG gene signature overexpression
DDR
Tregs-H
MSI-H/dMMR
NT5E overexpression
Chr del(9)(p21.3)
TP53 expression
HAS3 expression
FGFR1 overexpression
DAPK1 underexpression
miR-155 underexpression
SMARCA4 mutation
KDM6A mutation
PTTG1 overexpression
TP53 mutation
MCAM overexpression
PLK1 overexpression
CCNE1 amplification
CTBP1 deletion
LAG3 expression
ACRBP amplification
CXCL11-H
CCL4 elevation
DDX39B overexpression
ADCYAP1 deletion
AXL overexpression + PD-L1 expression
GNAS amplification
LRP10 deletion
CXCL13 elevation
TNFSF13B elevation
UGT1A9 expression
SULT1A3 amplification
PAI1-H
IL13RA2 overexpression
CXCL12-H
CXCR4 overexpression
SETD2 mutation
AR-V7 positive
EPAS1 overexpression